Clinical features of adverse reactions associated with telbivudine

World Journal of Gastroenterology

Volumn 14, Issue 22, 2008, Pages 3549-3553

  Zhang, Xue Song ^a   Jin, Rui ^a   Zhang, Shi Bin ^a   Tao, Ming Ling ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Adverse drug reaction; Hepatitis B; Mitochondria; Nucleoside analogue; Telbivudine

Indexed keywords

ADEFOVIR; ANTIRHEUMATIC AGENT; ENTECAVIR; INTERFERON; LAMIVUDINE; MECOBALAMIN; PROPAFENONE; TELBIVUDINE; VITAMIN B GROUP;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIAGNOSTIC ERROR; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART ARRHYTHMIA; HEMOGLOBIN BLOOD LEVEL; HEPATITIS B; HUMAN; KIDNEY FUNCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LIVER FUNCTION; MALE; MONOTHERAPY; MUSCLE WEAKNESS; MYALGIA; MYOCARDITIS; MYOPATHY; NEPHROTOXICITY; NEURALGIA; NEURITIS; NEUROLOGIC DISEASE; PARESTHESIA; RISK FACTOR; SIDE EFFECT; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL;

EID: 54449091138     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3549     Document Type: Article

References (31)

1. Bryant ML, Bridges EG, Pladdi L, Faraj A, Loi AG, Pierra C, Dukhan D, Gosselin G, Imbach JL, Hernandez B, Juodawlkis A, Tennant B, Korba B, Cote P, Marion P, Cretton-Scott E, Schinazi RF, Sommadossi JP. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001; 45: 229-235
2. Liang YL, Huang CX. New drug for Chronic Hepatitis B-telbivudine (review). Zhongnan Yaoxue 2007; 5: 285-287
3. Mondelli M. [New treatment options in chronic hepatitis B] Infez Med 2008; 16: 5-14
4. Borgia G, Gentile I. Treating chronic hepatitis B: today and tomorrow. Curr Med Chem 2006; 13: 2839-2855
5. Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H, Wan M, Chen C, Wu S, Chen Y, Xu J, Wang Q, Wei L, Chao G, Constance BF, Harb G, Brown NA, Jia J. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47: 447-454
6. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588
7. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown NA. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-536
8. Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, Chao YC, Myers RP, Minuk GY, Jeffers L, Sievert W, Bzowej N, Harb G, Kaiser R, Qiao XJ, Brown NA. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147: 745-754
9. Matthews SJ. Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther 2007; 29: 2635-2653
10. Zhang HF. Mitochondria disease (lecture). Ningxia Yixue Zazhi 2003; 9: 574-575
11. Jackson MJ, Schaefer JA, Johnson MA, Morris AA, Turnbull DM, Bindoff LA. Presentation and clinical investigation of mitochondrial respiratory chain disease. A study of 51 patients. Brain 1995; 118 (Pt 2): 339-357
12. Servidei S, Zeviani M, Manfredi G, Ricci E, Silvestri G, Bertini E, Gellera C, Di Mauro S, Di Donato S, Tonali P. Dominantly inherited mitochondrial myopathy with multiple deletions of mitochondrial DPA: clinical, morphologic, and biochemical studies. Neurology 1991; 41: 1053-1059
13. Hammans SR, Sweeney MG, Brockington M, Lennox GG, Lawton NF, Kennedy CR, Morgan-Hughes JA, Harding AE. The mitochondrial DNA transfer RNA(Lys)A→G(8344) mutation and the syndrome of myoclonic epilepsy with ragged red fibres (MERRF). Relationship of clinical phenotype to proportion of mutant mitochondrial DNA. Brain 1993; 116 (Pt 3): 617-632
14. Huoponen K, Vilkki J, Aula P, Nikoskelainen EK, Savontaus ML. A new mtDNA mutation associated with Leber hereditary optic neuroretinopathy. Am J Hum Genet 1991; 48: 1147-1153
15. Sherratt EJ, Thomas AW, Alcolado JC. Mitochondrial DNA defects: a widening clinical spectrum of disorders. Clin Sci (Lond) 1997; 92: 225-235
16. Wang YJ. The development of the therapy in mitochondria disease. Guowai Yixue Shenjingbingxue Shenjing Waikexue Shouce 1996; 23: 191-193
17. Chen QT, Wu LJ, Wu QZ, Yuan Y, Jia Z, Zhang QR, Gao H, Shi ZH. Primary mitochon-drial myopathy and encephalomyopathy (A report of 53 cases). Zhongguo Shenjing Jingshen Jibing Zazhi 1994; 20: 16-18
18. Fu ZX, Zhao D. The analysis of 25 cases of mitochondria disease. Henan Yike Daxue Xuebao 2000; 35: 451
19. Deng AP. Efficacy and safety of entecavir in treatment of Chronic Hepatitis B. Zhongguo Xinyao Yu Linchuang Zazhi 2005; 4: 326-329
20. Ray AS, Feng JY, Murakami E, Chu CK, 5chinazi RF, Anderson KS. Interaction of 2′-deoxyguanosine triphosphate analogue inhibitors of HIV reverse transcriptase with human mitochondrial DNA polymerase gamma. Antivir Chem Chemother 2007; 18: 25-33
21. Feng JY, Murakami E, Zorca SM, Johnson AA, Johnson KA, Schinazi RF, Furman PA, Anderson KS. Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2′,3′-dideoxy-5- fluoro-3′-thiacytidine-triphosphate analogs by human immunodeficeincy virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob Agents Chemother 2004; 48: 1300-1306
22. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, Johnson KA. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276: 40847-40857
23. Gu CH, Luo KX. Hepatitis B Basic Biology and Clinical Science. 2th ed. In: Anti-virus therapy: Nucleoside analogues, Peking: People's Medical Publishing House, 2000: 396-400
24. Jiang J, Hu P, Wang HY, Shen K, Brown NA, Zhou XJ. [Study on the pharmacokinetic profile of telbivudine] Zhonghua Ganzangbing Zazhi 2006; 14: 811-813
25. Zhou XJ, Fielman BA, Lloyd DM, Chao GC, Brown NA. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob Agents Chemother 2006; 50: 2309-2315
26. Zhou XJ, Lloyd DM, Chao GC, Brown NA. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J Clin Pharmacol 2006; 46: 275-281
27. Zhou XJ, Lim SG, Lloyd DM, Chao GC, Brown NA, Lai CL. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob Agents Chemother 2006; 50: 874-879
28. Zerbini A, Pilli M, Bord C, Fisicaro P, Penna A, Di Vincenzo P, Giuberti T, Orlandini A, Raffa G, Pollicino T, Raimondo G, Ferrari C, Missale G. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008; 134: 1470-1481
29. Ferreira MS, Borges AS. [Advances in the treatment of hepatitis B] Rev Soc Bras Med Trop 2007; 40: 451-462
30. Marcellin P, Lada O, Asselah T. Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine. Hepatol Res 2007; 37: S55-S61
31. Merup M, Aberg W, L_dofvenberg E, Svensson E, Engman K, Paul C, Garduff A. Symptoms symptom distress and health-related quality of life in patients with polycythaemia vera or essential thrombocythaemia during treatment with interferon-alpha. Acta Oncol 2002; 41: 50-55